DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- IterumTherapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and ...
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- IterumTherapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and ...